Susan Halli-Demeter, DNP, NP

Objectives:

1.         Discuss the role of PCSK9i therapy in treating individuals with FH and ASCVD who are not at goal on optimal lipid lowering therapy.

2.         Evaluate the data from FOURIER and ODDESSEY and how to put the results into practice.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s), please go here to review disclosures.